December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Regression of Ocular Neovascularization by Increased Expression of Pigment Epithelium-Derived Factor
Author Affiliations & Notes
  • K Mori
    Department of Ophthalmology and Neuroscience Johns Hopkins University School of Medicine Baltimore MD
  • PL Gehlbach
    Department of Ophthalmology and Neuroscience Johns Hopkins University School of Medicine Baltimore MD
  • A Ando
    Department of Ophthalmology and Neuroscience Johns Hopkins University School of Medicine Baltimore MD
  • D McVey
    GenVec Gaithersberg MD
  • L Wei
    GenVec Gaithersberg MD
  • PA Campochiaro
    Department of Ophthalmology and Neuroscience Johns Hopkins University School of Medicine Baltimore MD
  • Footnotes
    Commercial Relationships   K. Mori, None; P.L. Gehlbach, None; A. Ando, None; D. McVey, GenVec E; L. Wei, GenVec E; P.A. Campochiaro, GenVec F, C, R; NovartisOphthalmics F, C, R; Alcon F; RW Johnson F. Grant Identification: Support: NIH Grant EY05951, 012609 and GenVec, Inc.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3914. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K Mori, PL Gehlbach, A Ando, D McVey, L Wei, PA Campochiaro; Regression of Ocular Neovascularization by Increased Expression of Pigment Epithelium-Derived Factor . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3914.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Several pharmacologic treatments have been demonstrated to reduce ocular neovascularization when administered prior to the onset of angiogenic stimuli, but none have been shown to cause regression of already established ocular neovascularization. In this study, we tested the effect of adenoviral vector-mediated pigment epithelium-derived factor (PEDF) gene transfer on established neovascularization in transgenic mice with expression of vascular endothelial growth factor (VEGF) in photoreceptors (rho/VEGF mice), and in a model of choroidal neovascularization. Methods: Two weeks after the onset of VEGF transgene expression in rho/VEGF mice, or 2 weeks after laser-induced rupture of Bruch’s membrane in wild type mice, subgroups of mice were sacrificed and the baseline amount of neovascularization was measured by image analysis. The remainder of the mice received an intravitreous or subretinal injection of adenoviral vector containing a PEDF expression construct (AdPEDF.11) or control vector (AdNull.11). Results: Seven days after injection in rho/VEGF mice or 10 days after injection in the choroidal neovascularization model, the amount of neovascularization in AdPEDF.11-injected eyes was significantly less than the baseline level, indicating that regression of neovascularization had occurred. There was TUNEL staining within choroidal neovascular lesions in eyes injected with AdPEDF.11. Eyes given a subretinal injection of AdNull.11 had no TUNEL-positive cells within areas of choroidal neovascularization, although there was some detected elsewhere in the retina. Conclusion: These data indicate that increased expression of PEDF causes regression of ocular neovascularization by promoting apoptosis of cells within neovascular lesions. PEDF gene delivery may represent a new treatment paradigm for patients with established ocular neovascularization.

Keywords: 419 gene transfer/gene therapy • 308 age-related macular degeneration • 566 retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×